Eli Lilly Financial Overview and Analysis

Hello. Would you like to create a new portfolio?

What industries is LLY in? What is its market cap, revenue, net income, and free cash flow?

Here is a summary of the financial and industry data for Eli Lilly and Company (symbol: LLY):

Company Overview

• Name: Eli Lilly and Company
• Ticker: LLY
• Exchange: NYSE
• IPO Date: June 1, 1972

Industries

Eli Lilly operates in several industries, including:

• Biotechnology
• Healthcare
• Immunotherapy
• Medicine
• Oncology
• Pharmaceuticals
• Research
• Logistics and Supply Chain
• Manufacturing
• Digital Health
• Bioinformatics
• Computational Biology
• Computational Chemistry
• Chemicals
• Distribution

Financial Metrics

• Market Cap: $878,725,657,308 (as of September 25, 2024)
• Revenue: $11,302,800,000
• Net Income: $2,967,000,000
• Free Cash Flow: $63,255,141
• Earnings Date: August 9, 2024

Observations

• Eli Lilly is a major player in the pharmaceutical and healthcare industries, with a strong focus on biotechnology and research.
• The company has a substantial market capitalization, indicating its significant presence in the market.
• The revenue and net income figures suggest a profitable operation, although the free cash flow is relatively modest compared to the net income.

Please remember to double-check all answers generated by the AI for accuracy.

Analyze LLY's 2024 full year earnings

It seems that I had to use fallback data for Eli Lilly's (LLY) financial analysis, specifically using the fiscal year 2023 data instead of the 2024 data. Therefore, I cannot provide a comparison between the two periods, but I can give you a detailed summary of the 2023 financial data that I retrieved.

Financial Summary for Eli Lilly (FY 2023)

1. Revenue and Income:

   • Revenue: $34.124 billion
   • Net Income: $5.240 billion
   • Gross Profit: $27.041 billion
   • Operating Income: $10.325 billion

2. Cash Flow:

   • Free Cash Flow: -$3.148 billion
   • Operating Cash Flow: Calculated as $5.240 billion (Net Income) + $1.527 billion (Depreciation & Amortization) - $3.055 billion (Change in Working Capital) = $3.712 billion

3. Profitability Metrics:

   • Gross Profit Margin: 79.25%
   • Operating Margin: 30.26%
   • Net Profit Margin: 15.36%
   • Return on Equity: 48.24%
   • Return on Assets: 8.19%
   • Return on Invested Capital: 29.15%

4. Liquidity and Solvency:

   • Current Ratio: 0.94 (indicating potential liquidity concerns as it is below 1)
   • Total Debt: $25.225 billion
   • Liabilities to Equity Ratio: 4.89 (indicating high leverage)

5. Per Share Metrics:

   • Earnings Per Share, Basic: $5.82
   • Earnings Per Share, Diluted: $5.80
   • Sales Per Share: $37.91
   • Equity Per Share: $11.97

6. Other Important Metrics:

   • Piotroski F-Score: 6 (indicating moderate financial health)
   • Net Debt / EBITDA: 2.60 (suggesting a moderate level of debt relative to earnings)

Price Metrics (as of February 21, 2024)

• Last Closing Price: $745.91
• Market Cap: $708.737 billion
• Price to Earnings Ratio (TTM): 133.32
• Price to Sales Ratio (TTM): 20.47
• Price to Book Value (TTM): 64.31

Observations

• Eli Lilly has strong profitability metrics with high margins and returns on equity and invested capital.
• The company has a high level of debt, as indicated by the liabilities to equity ratio and net debt to EBITDA ratio.
• The current ratio below 1 suggests potential liquidity issues, meaning the company may struggle to cover short-term liabilities with its short-term assets.
• The negative free cash flow indicates that the company is spending more on capital expenditures and other investments than it is generating in cash from operations.

Recommendation

Eli Lilly appears to be a profitable company with strong returns, but potential investors should be cautious about its high leverage and liquidity concerns. The high price-to-earnings and price-to-book ratios suggest that the stock may be overvalued.

Rating: 3/5

This rating reflects the company's strong profitability but also considers the high debt levels and liquidity concerns. Please remember that this is not financial advice, and you should conduct your own research before making investment decisions.

For more detailed information, you can refer to the source provided:

• Source for Eli Lilly's FY 2023 Earnings
• Link to Eli Lilly stock page